JP7575096B2 - ワクチン組成物 - Google Patents

ワクチン組成物 Download PDF

Info

Publication number
JP7575096B2
JP7575096B2 JP2021510553A JP2021510553A JP7575096B2 JP 7575096 B2 JP7575096 B2 JP 7575096B2 JP 2021510553 A JP2021510553 A JP 2021510553A JP 2021510553 A JP2021510553 A JP 2021510553A JP 7575096 B2 JP7575096 B2 JP 7575096B2
Authority
JP
Japan
Prior art keywords
kda
protein
composition
peptide tag
spytag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021510553A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523937A (ja
Inventor
ビスワス，スミ
ジン，ジン
ダブズ，レベッカ・アリス
ラベー，ジュヌビエーブ・マリー・カトリーヌ
Original Assignee
スパイバイオテック・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1807378.3A external-priority patent/GB201807378D0/en
Priority claimed from GBGB1807376.7A external-priority patent/GB201807376D0/en
Application filed by スパイバイオテック・リミテッド filed Critical スパイバイオテック・リミテッド
Publication of JP2021523937A publication Critical patent/JP2021523937A/ja
Priority to JP2024133744A priority Critical patent/JP2024156964A/ja
Application granted granted Critical
Publication of JP7575096B2 publication Critical patent/JP7575096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18523—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021510553A 2018-05-04 2019-05-03 ワクチン組成物 Active JP7575096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024133744A JP2024156964A (ja) 2018-05-04 2024-08-09 ワクチン組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1807378.3A GB201807378D0 (en) 2018-05-04 2018-05-04 Vaccine composition
GB1807376.7 2018-05-04
GB1807378.3 2018-05-04
GBGB1807376.7A GB201807376D0 (en) 2018-05-04 2018-05-04 HMCV Vaccine Composition
PCT/GB2019/051245 WO2019211630A2 (en) 2018-05-04 2019-05-03 Vaccine composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024133744A Division JP2024156964A (ja) 2018-05-04 2024-08-09 ワクチン組成物

Publications (2)

Publication Number Publication Date
JP2021523937A JP2021523937A (ja) 2021-09-09
JP7575096B2 true JP7575096B2 (ja) 2024-10-29

Family

ID=66484095

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021510553A Active JP7575096B2 (ja) 2018-05-04 2019-05-03 ワクチン組成物
JP2024133744A Pending JP2024156964A (ja) 2018-05-04 2024-08-09 ワクチン組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024133744A Pending JP2024156964A (ja) 2018-05-04 2024-08-09 ワクチン組成物

Country Status (11)

Country Link
US (2) US12433944B2 (enExample)
EP (1) EP3787676A2 (enExample)
JP (2) JP7575096B2 (enExample)
KR (1) KR20210013571A (enExample)
CN (2) CN120040601A (enExample)
AU (2) AU2019263706B2 (enExample)
BR (1) BR112020022393A2 (enExample)
CA (1) CA3099381A1 (enExample)
IL (1) IL278418B2 (enExample)
SG (1) SG11202010821TA (enExample)
WO (1) WO2019211630A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024156964A (ja) * 2018-05-04 2024-11-06 スパイバイオテック・リミテッド ワクチン組成物

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201917265D0 (en) * 2019-11-27 2020-01-08 Univ Sheffield Bonded neurotoxins
JP7801221B2 (ja) * 2019-12-11 2026-01-16 ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ 流行性耳下腺炎ウイルスおよび麻疹ウイルスの免疫原およびそれらの使用
CN114634578B (zh) * 2020-12-15 2024-04-02 榕森生物科技(北京)有限公司 针对新型冠状病毒感染的疫苗组合物
MX2023007319A (es) * 2020-12-18 2023-08-08 Univ Copenhagen Vacunas de acido nucleico.
US20240240203A1 (en) * 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
CN114736272B (zh) * 2022-02-21 2022-09-06 悦康药业集团股份有限公司 一种优化病毒膜融合抑制剂的方法及广谱抗冠状病毒脂肽和应用
CN115920026B (zh) * 2022-04-02 2023-11-14 中山大学 耐热性多聚体蛋白支架、耐热性多聚体蛋白支架在疫苗中的应用
CN115010812B (zh) * 2022-04-12 2024-06-21 河南省龙星生物科技有限公司 一种非洲猪瘟抗原介导细胞免疫的多聚体及应用
CN116041536A (zh) * 2022-09-15 2023-05-02 山西大学 一种多接头自组装蛋白纳米颗粒的制备方法与应用
CN117462666B (zh) * 2022-09-30 2024-07-30 烟台派诺生物技术有限公司 一种预防或治疗水痘-带状疱疹病毒相关疾病的免疫组合物产品及其制备方法
CN117264074A (zh) * 2023-01-12 2023-12-22 东沃同泰(凤城)生物工程有限公司 靶向DCs递送的耐热性纳米颗粒蛋白、纳米载体、免疫原性复合物和纳米颗粒疫苗及应用
CN117050149B (zh) * 2023-05-19 2025-12-12 珠海丽凡达生物技术有限公司 包含人呼吸道合胞病毒抗原的免疫组合物及其制备方法和应用
CN117264081B (zh) * 2023-11-21 2025-03-21 华南理工大学 一种双肽受体激动剂及其制备方法与应用
CN118373888B (zh) * 2024-06-27 2024-08-30 普大生物科技(泰州)有限公司 一种水痘-带状疱疹病毒纳米颗粒蛋白及其制备方法和应用
WO2026028158A1 (en) * 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474914A (en) 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US7951384B2 (en) * 2005-08-05 2011-05-31 University Of Massachusetts Virus-like particles as vaccines for paramyxovirus
KR101617895B1 (ko) 2007-12-24 2016-05-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 재조합 ｒｓｖ 항원
WO2011009877A1 (de) 2009-07-24 2011-01-27 Basf Se Flammgeschützte polyamidformmassen
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
US20130164289A1 (en) 2010-09-09 2013-06-27 Virginia Commonwealth University Human cytomegalovirus vaccine
CN107875382B (zh) * 2011-11-11 2024-03-08 变异生物技术公司 用于治疗巨细胞病毒的组合物和方法
JP2015522581A (ja) 2012-07-06 2015-08-06 ノバルティス アーゲー サイトメガロウイルスタンパク質の複合体
PT2970398T (pt) 2013-03-13 2024-06-07 The Us Secretary Department Ofhealth And Human Servic Proteínas f de pré-fusão do vsr e sua utilização
NZ721908A (en) 2013-12-20 2022-12-23 Massachusetts Gen Hospital Combination therapy with neoantigen vaccine
EP3015475A1 (en) 2014-10-31 2016-05-04 Novartis AG Mammalian cells expressing cytomegalovirus antigens
GB201509782D0 (en) 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN106081304A (zh) 2016-07-27 2016-11-09 佛山市高明金荣华乐金属制品有限公司 一种新型可折叠箱体及其拆装方法
GB201705750D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd Peptide ligase and use therof
GB201706430D0 (en) 2017-04-24 2017-06-07 Univ Oxford Innovation Ltd Proteins and peptide tags with enhanced rate of spontaneous isopeptide bond formation and uses thereof
WO2019211630A2 (en) * 2018-05-04 2019-11-07 SpyBiotech Limited Vaccine composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112921A1 (en) 2015-01-15 2016-07-21 University Of Copenhagen Virus-like particle with efficient epitope display

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nature Communications，2015年，Vol.6:8143，p.1-12
PLOS Pathogens，2014年，Vol.10, No.11, e1004524，p.1-23
Vaccine，2013年，Vol.31，p.2310-2316

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024156964A (ja) * 2018-05-04 2024-11-06 スパイバイオテック・リミテッド ワクチン組成物

Also Published As

Publication number Publication date
AU2019263706A1 (en) 2020-11-19
KR20210013571A (ko) 2021-02-04
WO2019211630A3 (en) 2019-12-05
IL278418B1 (en) 2023-09-01
SG11202010821TA (en) 2020-11-27
IL278418B2 (en) 2024-01-01
CA3099381A1 (en) 2019-11-07
CN112638411A (zh) 2021-04-09
US20260007740A1 (en) 2026-01-08
AU2026201020A1 (en) 2026-03-05
US12433944B2 (en) 2025-10-07
EP3787676A2 (en) 2021-03-10
JP2021523937A (ja) 2021-09-09
WO2019211630A2 (en) 2019-11-07
AU2019263706B2 (en) 2026-02-26
CN120040601A (zh) 2025-05-27
CN112638411B (zh) 2025-03-04
IL278418A (enExample) 2020-12-31
BR112020022393A2 (pt) 2021-02-02
JP2024156964A (ja) 2024-11-06
US20210128717A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
US20260007740A1 (en) Vaccine composition
US11786591B2 (en) Recombinant metapneumovirus F proteins and their use
JP6469081B2 (ja) 安定化された可溶性融合前ｒｓｖｆポリペプチド
US12447207B2 (en) Human cytomegalovirus gB polypeptide
TWI874544B (zh) 變異型rsv f蛋白質及其利用
CN114127101A (zh) 用于治疗或预防呼吸道感染的亚单位疫苗
CN105792842A (zh) 埃巴病毒疫苗
US11806394B2 (en) Protein-based nanoparticle vaccine for metapneumovirus
CN116096407A (zh) 重组人偏肺病毒f蛋白及其用途
KR20180131584A (ko) 안정화된 용해성 융합-전 rsv f 단백질
JP5557254B2 (ja) 薬物運搬体並びにこれを利用したアジュバントおよびワクチン
WO2019092002A1 (en) Pharmaceutical compositions for treatment or prevention of viral infections
EA039124B1 (ru) Стабилизированные f-белки rsv до слияния
CN121013729A (zh) 不具有异源三聚化结构域的稳定化的三聚rsv融合蛋白
WO2024227418A1 (zh) Rsv f蛋白的突变体
CN112823021A (zh) 稳定化的丝状病毒糖蛋白三聚体
HK40127919A (zh) 疫苗组合物
JP2023002492A (ja) 変異型ｒｓｖ ｆタンパク質を含む医薬組成物
CN121620537A (zh) Rsv和hmpv融合f蛋白及其用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231026

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240131

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240412

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240809

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241009

R150 Certificate of patent or registration of utility model

Ref document number: 7575096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150